Literature DB >> 22334123

Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine.

Mehmet Sofuoglu1, Aryeh I Herman, Haleh Nadim, Peter Jatlow.   

Abstract

The ratio of nicotine metabolites (trans-3'-hydroxycotinine (3HC) to cotinine) correlates with nicotine clearance. In previous studies, high nicotine metabolite ratio (NMR) predicted poor outcomes for smoking cessation treatment with nicotine patch. The underlying mechanisms that associate NMR with treatment outcomes have not been fully elucidated. A total of 100 smokers were divided into quartiles based on their baseline plasma NMR. Following overnight abstinence, smokers received saline followed by escalating intravenous doses of nicotine (0.5 and 1.0 mg/70 kg) given 30 min apart. The effects of nicotine on subjective, plasma cortisol, heart rate, and systolic and diastolic blood pressure measures were obtained. Smokers in the first NMR quartile (slower metabolizers) had lower Fagerstrom Test for Nicotine Dependence (FTND) scores, suggesting lower levels of dependence. In contrast, smokers in the fourth NMR quartile (faster metabolizers) reported greater craving for cigarettes following overnight abstinence from smoking and reported greater ratings of nicotine-induced good drug effects, drug liking, and wanting more drug. Higher NMR was also associated with greater heart rate increases in response to nicotine. These results suggest that enhanced nicotine reward and cigarette craving may contribute to the poor treatment response in smokers with high NMR. These findings warrant further investigation, especially in treatment-seeking smokers undergoing cessation treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334123      PMCID: PMC3327855          DOI: 10.1038/npp.2011.336

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

1.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

Authors:  Y Rao; E Hoffmann; M Zia; L Bodin; M Zeman; E M Sellers; R F Tyndale
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

2.  Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine.

Authors:  N L Benowitz; S Zevin; P Jacob
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

3.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

4.  Positive reactions to tobacco predict relapse after cessation.

Authors:  David R Strong; Adam M Leventhal; Daniel P Evatt; Suzanne Haber; Benjamin D Greenberg; David Abrams; Raymond Niaura
Journal:  J Abnorm Psychol       Date:  2011-05-16

5.  Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity.

Authors:  Peyton Jacob; Lisa Yu; Minjiang Duan; Lita Ramos; Olivia Yturralde; Neal L Benowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-12-21       Impact factor: 3.205

6.  Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.

Authors:  Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-06       Impact factor: 4.254

7.  Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.

Authors:  E M Sellers; H L Kaplan; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2000-07       Impact factor: 6.875

Review 8.  Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence.

Authors:  Oliver West; Peter Hajek; Hayden McRobbie
Journal:  Psychopharmacology (Berl)       Date:  2011-05-20       Impact factor: 4.530

9.  Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler.

Authors:  Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove
Journal:  Int J Neuropsychopharmacol       Date:  2010-10-29       Impact factor: 5.176

10.  Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.

Authors:  Gary E Swan; Christina N Lessov-Schlaggar; Andrew W Bergen; Yungang He; Rachel F Tyndale; Neal L Benowitz
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

View more
  65 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Authors:  Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

3.  Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.

Authors:  Ahmed El-Boraie; Taraneh Taghavi; Meghan J Chenoweth; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Nicole L Nollen; Neal L Benowitz; Rachel F Tyndale
Journal:  Addict Biol       Date:  2019-02-27       Impact factor: 4.280

4.  The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.

Authors:  Meghan J Chenoweth; Robert A Schnoll; Maria Novalen; Larry W Hawk; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Nicotine Tob Res       Date:  2015-06-11       Impact factor: 4.244

5.  Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

6.  Use of hormonal contraceptives and smoking cessation: A preliminary report.

Authors:  Alicia M Allen; Samantha Carlson; Lynn E Eberly; Dorothy Hatsukami; Megan E Piper
Journal:  Addict Behav       Date:  2017-08-04       Impact factor: 3.913

7.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

Review 8.  Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation.

Authors:  Andrea H Weinberger; Philip H Smith; Sharon S Allen; Kelly P Cosgrove; Michael E Saladin; Kevin M Gray; Carolyn M Mazure; Cora Lee Wetherington; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

Review 9.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

10.  Accuracy of prenatal smoking data from Washington State birth certificates in a population-based sample with cotinine measurements.

Authors:  Susan Searles Nielsen; Russell L Dills; Michael Glass; Beth A Mueller
Journal:  Ann Epidemiol       Date:  2013-12-28       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.